GlassScriptPhysician profile
Megan C Macneil
NPI 1437107869
$5,765.37
in general payments reported to CMS, 2019-2025
29 companies · $2,351 in 2025
The $2,351 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $173 · 2021: $12.10 · 2022: $683 · 2023: $843 · 2024: $763 · 2025: $2,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,948 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,948.05 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,654.21 | 2019-2025 | |
| Ucb, INC. | $444.13 | 2019-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $377.69 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $329.47 | 2019-2024 | Benlysta |
| Amgen INC. | $311.75 | 2019-2025 | Tavneos, Evenity, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $302.72 | 2022-2025 | Saphnelo |
| Pfizer INC. | $264.89 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $191.56 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $142.50 | 2019-2023 | Orencia |
| Radius Health, INC. | $121.54 | 2019-2025 | Tymlos |
| Genentech USA, INC. | $84.64 | 2019-2023 | Actemra |
| Fresenius Kabi USA, LLC | $72.85 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.30 | 2022-2023 | Ofev |
| Ani Pharmaceuticals, INC. | $49.00 | 2022-2025 | Purified Cortrophin Gel |
| Sobi, INC | $44.12 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $35.90 | 2025 | Vegzelma |
| Scilex Pharmaceuticals INC. | $31.77 | 2024 | |
| Sandoz INC. | $31.31 | 2025 | Jubbonti |
| Genzyme Corporation | $29.58 | 2024-2025 | |
| Mylan Institutional INC. | $24.25 | 2023 | Hulio |
| Organon LLC | $23.89 | 2025 | Hadlima |
| Mallinckrodt Hospital Products INC. | $21.77 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $21.30 | 2019 | |
| Celgene Corporation | $20.72 | 2019 | |
| Janssen Biotech, INC. | $19.36 | 2024 | Tremfya |
| Gilead Sciences, INC. | $17.15 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.47 | 2019 | |
| Avion Pharmaceuticals | $15.27 | 2020 | |
| Kyowa Kirin, INC. | $14.26 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Macneil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.